A higher risk of adult psychotic experiences is associated with childhood cat ownership.

Published Date: 24 Apr 2023

Canada: The Journal of Psychiatric Research recently reported that childhood cat ownership, particularly with rodent-hunting cats,.

Read Full News

Latest News

What the Next Accelerated TMS Trial Should Test, With Jonathan Downar, MD Jonathan Downar, MD, PhD

Downar outlines the randomized trial needed to confirm optimal TMS dosing and addresses a safety ceiling on total pulses.

Q3 2026 Recap: Psychiatry News and Updates

Q3 2026 Recap: Psychiatry News and Updates

5 Psychiatry Headlines You Missed in September 2026

5 Psychiatry Headlines You Missed in September 2026

What The FDA Psychedelic Hearing Means for Psychiatrists

What The FDA Psychedelic Hearing Means for Psychiatrists

TMS for MDD Is Changing Fast. Here's What Psychiatrists Need to Know Andrew Leuchter, MD, Scott A. Wilke, MD, PhD, Linda Carpenter, MD

New accelerated TMS protocols and an FDA-approved at-home device are changing how psychiatrists treat MDD after antidepressant failure.

Emerge Phase 3: DT120 Shows Rapid, Durable Relief in MDD John Sonnenberg, PhD

John Sonnenberg, PhD, reflects on Emerge phase 3 topline data for DT120 in MDD, including MADRS outcomes, remission rates, and what comes next.

Todays Updates

The HCPFive: Top News for Healthcare Providers from the Week of 10/25

The HCPFive: Top News for Healthcare Providers from the Week of 10/25

Q&A: Asthma Remission from Year 1 To Year 2 With Depemokimab

Q&A: Asthma Remission from Year 1 To Year 2 With Depemokimab

Deep TMS Reduces Suicidal Ideation by 70% in MDD, With Owen Muir, MD Owen Muir, MD, DFAACAP, FCTMSS

A secondary analysis found the SWIFT accelerated protocol eased suicidal ideation faster than standard daily deep TMS dosing in major depressive disorder.

Benitec Reports Positive Interim Results for BB-301 in Oculopharyngeal Muscular Dsytrophy Marco Meglio

Interim phase 1b/2a data showed all patients treated with high- or low-dose BB-301 for oculopharyngeal muscular dystrophy met formal response criteria.

This Week on NeurologyLive® — November 2, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Zola-Cel and Treatment-Free Remission: What the BREAKFREE-2 Data Show Marco Meglio, Jeffrey Cohen, MD

Jeffrey Cohen, MD, professor of neurology and staff physician at the Cleveland Clinic Mellen Center for Multiple Sclerosis, discusses interim BREAKFREE-2 findings for zola-cel, a CD19-directed CAR T cell therapy, in relapsing and progressive MS.

ASN Kidney Week 2026 Recap: 8 Key Updates in Kidney Disease to Know

ASN Kidney Week 2026 Recap: 8 Key Updates in Kidney Disease to Know

Todays Updates

The HCPFive: Top News for Healthcare Providers from the Week of 10/25

The HCPFive: Top News for Healthcare Providers from the Week of 10/25

Q&A: Asthma Remission from Year 1 To Year 2 With Depemokimab

Q&A: Asthma Remission from Year 1 To Year 2 With Depemokimab

Deep TMS Reduces Suicidal Ideation by 70% in MDD, With Owen Muir, MD Owen Muir, MD, DFAACAP, FCTMSS

A secondary analysis found the SWIFT accelerated protocol eased suicidal ideation faster than standard daily deep TMS dosing in major depressive disorder.

Benitec Reports Positive Interim Results for BB-301 in Oculopharyngeal Muscular Dsytrophy Marco Meglio

Interim phase 1b/2a data showed all patients treated with high- or low-dose BB-301 for oculopharyngeal muscular dystrophy met formal response criteria.

This Week on NeurologyLive® — November 2, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Zola-Cel and Treatment-Free Remission: What the BREAKFREE-2 Data Show Marco Meglio, Jeffrey Cohen, MD

Jeffrey Cohen, MD, professor of neurology and staff physician at the Cleveland Clinic Mellen Center for Multiple Sclerosis, discusses interim BREAKFREE-2 findings for zola-cel, a CD19-directed CAR T cell therapy, in relapsing and progressive MS.

ASN Kidney Week 2026 Recap: 8 Key Updates in Kidney Disease to Know

ASN Kidney Week 2026 Recap: 8 Key Updates in Kidney Disease to Know

Latest News

Downar outlines the randomized trial needed to confirm optimal TMS dosing and addresses a safety ceiling on total pulses.

Q3 2026 Recap: Psychiatry News and Updates

5 Psychiatry Headlines You Missed in September 2026

What The FDA Psychedelic Hearing Means for Psychiatrists

New accelerated TMS protocols and an FDA-approved at-home device are changing how psychiatrists treat MDD after antidepressant failure.

John Sonnenberg, PhD, reflects on Emerge phase 3 topline data for DT120 in MDD, including MADRS outcomes, remission rates, and what comes next.

News All Time

3 Psychiatry Headlines You Missed in July 2026 Chelsie Derman

Centanafadine FDA approval, DT120 EMERGE trial results, and COMP360 psilocybin data headline this month's psychiatry coverage.

FDA Approves Centanafadine for ADHD in Adults, Children Aged ≥ 6 Years Chelsie Derman

The first-in-class NDSRI showed significant symptom improvement as early as week 1 across 4 phase 3 trials but carries boxed warnings for suicidality and abuse potential.

Ketamine, Psychedelics Share Neuroimmune Signature in TRD Chelsie Derman

A biomarker study links immune signaling (IL-7/IL-15) and brain gamma-wave activity to ketamine response in TRD.

Metabolic Traits Differentiate AERS+, AERS− MDD Subtypes, With Arvid Harder Arvid Harder

New genome-wide data show AERS+ and AERS− subtypes of major depressive disorder diverge in heritability and metabolic genetic correlations.

Voyage: DT120 ODT Reduces Anxiety in Phase 3 GAD Trial Chelsie Derman

DT120 ODT produced a 5.4-point placebo-adjusted HAM-A reduction at week 12 in the phase 3 Voyage trial for generalized anxiety disorder.

AERS Subtypes Show Distinct Genetic Architecture in MDD Arvid Harder

A genome-wide study of > 460,000 individuals identify 27 loci separating AERS+ and AERS− subtypes of major depressive disorder by metabolic profile.

MDMA-Assisted Therapy NDA Resubmitted to FDA for PTSD Chelsie Derman

Resilient Pharmaceuticals has resubmitted its MDMA-assisted therapy NDA for PTSD without a new phase 3 trial, MAPS reported.

TMS Sessions Reduced From 38 Minutes to 3, With Jonathan Downar, MD, PhD Jonathan Downar, MD, PhD

Downar says shorter sessions, accelerated schedules, and expanding neuroimaging maps have made TMS effective for more patients in far fewer visits.

Do More TMS Pulses Track with Better Depression Outcomes? Jonathan Downar, MD, PhD

A new meta-analysis found total pulse count predicted outcomes in a roughly linear pattern across sham-controlled trials of accelerated rTMS.

DT120 ODT Receives Second FDA Breakthrough Therapy Designation in MDD Chelsie Derman

The FDA granted DT120 (lysergide) ODT Breakthrough Therapy designation for MDD, citing promising phase 3 Emerge data.

Lower TMS Intensity Correlates With Greater Depression Improvement Chelsie Derman

A randomized TMS trial found lower DLPFC electric-field strength, not higher intensity, correlated with greater depression improvement.

Q&A: Accelerated TMS Speeds Suicidal Ideation Relief, With Owen Muir, MD Owen Muir, MD, DFAACAP, FCTMSS

SWIFT accelerated Deep TMS resolved suicidal ideation faster than standard dosing, Owen Muir, MD, says.

ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD

ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD

Q&A: Woolley on UMBRAA's Multidrug Approach to Psilocybin Trial Masking

Q&A: Woolley on UMBRAA's Multidrug Approach to Psilocybin Trial Masking

Phase 3 PARADIGM: HLP003 (Psilocibin-d10) for Adjunctive MDD Use

Phase 3 PARADIGM: HLP003 (Psilocibin-d10) for Adjunctive MDD Use

Walmart Pasta Recall; 'Ketamine Bladder' in Kids; Panettiere's Cause of Death

Health news and commentary gathered by MedPage Today staff

Recommended News For You

Research Indicates that First-Line Immunotherapy Is Enough for Elderly NSCLC Patients?

The standard for high-risk prostate cancer is supported by a study using high-dose RT and long-term ADT.

younger kidney cancer survivors are more susceptible to heart problems.

New drug combination shows good results in patients with HPV-negative head and neck cancer

A study suggests that you should disregard the "pack-years" when determining your eligibility for lung cancer screening.

The Effect of Common Steroids on Cancer Treatments.

FDA Approves Iberdomide Combo for Multiple Myeloma

Recommended Articles For You

Risk Assessment of Hemolysis During Mechanical Circulatory Support 

Base Editing for Rare Hematologic Disease: Advances, Mechanisms, and Clinical Implications 

Metabolic Competition Within the Tumor Ecosystem: Mechanisms, Clinical Relevance, and Therapeutic Advances 

Integrated Models in Hematology for Specialists 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Schizophrenia patients are motivated by music therapy.

2.

Pediatric high-grade gliomas: Research reveals effective targeting with avapritinib

3.

Cancer deaths expected to rise to over 18 million in 2050, nearly 75% more than in 2024

4.

Breast Cancer Genetic Testing Need in Black Women Identified

5.

Products for Intimate Care and Cancer; Boost for Colorectal Cancer Stool Tests; Ultrasonic Biopsy?

1.

Clonal Hematopoiesis and Healthy Aging: Clinical Implications, Mechanisms, and Emerging Perspectives

2.

Understanding Sideroblastic Anemia and its Symptoms 

3.

Targeted Degradation in Leukemia: Mechanisms, Clinical Implications, and Therapeutic Advances

4.

Age-Dependent Megakaryocyte Development: Mechanisms, Clinical Implications, and Future Directions

5.

Unlocking the Potential of Trabectedin: A Novel Therapy for Cancer Treatment

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.

2.

First-Line Maintenance Therapy for Metastatic Urothelial Carcinoma: Bridging Clinical Practice and Trials

3.

Common Cancer Myths Debunked

4.

Blood Clotting Disorders Explained

5.

Understanding Blood Clotting Disorders

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot